title: Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
abstract: BACKGROUND
  Taxol is a microtubule stabilizing agent that arrests cells in mitosis leading to cell death. Taxol is widely used to treat breast cancer, but resistance occurs in 25-69% of patients and it is vital to understand how Taxol resistance develops to improve chemotherapy. The effects of chemotherapeutic agents are overcome by survival signals that cancer cells receive. We focused our studies on autotaxin, which is a secreted protein that increases tumor growth, aggressiveness, angiogenesis and metastasis. We discovered that autotaxin strongly antagonizes the Taxol-induced killing of breast cancer and melanoma cells by converting the abundant extra-cellular lipid, lysophosphatidylcholine, into lysophosphatidate. This lipid stimulates specific G-protein coupled receptors that activate survival signals.
  
  
  RESULTS
  In this study we determined the basis of these antagonistic actions of lysophosphatidate towards Taxol-induced G2/M arrest and cell death using cultured breast cancer cells. Lysophosphatidate does not antagonize Taxol action in MCF-7 cells by increasing Taxol metabolism or its expulsion through multi-drug resistance transporters. Lysophosphatidate does not lower the percentage of cells accumulating in G2/M by decreasing exit from S-phase or selective stimulation of cell death in G2/M. Instead, LPA had an unexpected and remarkable action in enabling MCF-7 and MDA-MB-468 cells, which had been arrested in G2/M by Taxol, to normalize spindle structure and divide, thus avoiding cell death. This action involves displacement of Taxol from the tubulin polymer fraction, which based on inhibitor studies, depends on activation of LPA receptors and phosphatidylinositol 3-kinase.
  
  
  CONCLUSIONS
  This work demonstrates a previously unknown consequence of lysophosphatidate action that explains why autotaxin and lysophosphatidate protect against Taxol-induced cell death and promote resistance to the action of this important therapeutic agent.
authors.affiliation: Department of Biochemistry (Signal Transduction Research Group), School of Molecular and Systems Medicine, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Nasser
authors.initials: N
authors.lastname: Samadi
authors.forename: Raie T
authors.initials: RT
authors.lastname: Bekele
authors.forename: Ing Swie
authors.initials: IS
authors.lastname: Goping
authors.forename: Luis M
authors.initials: LM
authors.lastname: Schang
authors.forename: David N
authors.initials: DN
authors.lastname: Brindley
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D016195:G2 Phase / Q000187:drug effects; D006801:Humans; D008246:Lysophospholipids / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology*; D008938:Mitosis / Q000187:drug effects*; D009097:Multienzyme Complexes / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology*; D043264:Phosphodiesterase I / Q000378:metabolism; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D000099189:Lysophospholipase D
chemical_list: D008246:Lysophospholipids; D009097:Multienzyme Complexes; D017239:Paclitaxel; D043264:Phosphodiesterase I; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases; D000099189:Lysophospholipase D; C032881:lysophosphatidic acid